Tag Archives: market access

Genentech (Roche) and Blueprint Medicines Collaborate to Increase Market Access

Both Gavreto and AYVAKIT are available through Blueprint’s specialty distribution network and two specialty pharmacies: Biologics by McKesson and PantherRx

Tanner Pharma Group Increasing Product Access With Named Patient Programs

A Named Patient Program (NPP) provides patients and physicians access to commercially approved medicines that are not available to them in their own country

Amplity Health Growing in Pharmaceutical Commercialization Market

Amplity Health looking to grow in pharmaceutical commercialization market with support of Altamont Capital Partners

Market Access Programs for Gene Therapies Increasing

Payers are planning for an increasing number of gene therapies being approved by developing new coverage programs

EVERSANA Integration Supports Patient-Centered Care

EVERSANA, while being formed, realized that its customers needed patient-centered, value-based care

Express Scripts Divesting United Biosource

Express Scripts Divesting United Biosource. Express Scripts and Avista Capital Partners, a leading private equity firm, recently announced that Avista has signed a definitive agreement to acquire United BioSource (UBC), a wholly-owned subsidiary of Express Scripts Holding Company. Founded in 2003 and headquartered in Blue Bell, Pennsylvania, UBC is a leading provider of pharmaceutical and patient […]

2015 Pharmaceutical Market Trend Vol. II

Raising the Bar on performance So as to force companies to get lean, activist investors employ the use of shareholder arbitrage. There is increasing selection in licensing and partnering opportunities, and a reduced margin for error. Market-authorization for one-time results in periodic reevaluation throughout the life cycle of the product. There is relentlessness in the […]

The Changing Roles of P&T Committees: A Look Back at the Last Decade and a Look Forward to 2020

Originally published at Pharmacy & Therapeutics – November 2014   http://www.nxtbook.com/nxtbooks/medimedia/pt_201411/src/forms/PT_November_2014_iframe_live.html#/38 Market and regulatory changes in the last 10 years, as well as the Affordable Care Act, have resulted in significant modifications to health care delivery models.  Traditionally, P&T committees limited the impact of their decisions to the populations associated with their hospital or health plan; […]